Adagene (ADAG) announced an investigator initiated Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer. The new study is expected to begin patient enrollment in April. The trial’s primary endpoint is the rate of Major Pathologic Response, defined as less than or equal to10% residual viable tumor in the surgical specimen, and will be evaluated in up to 20 patients. Secondary endpoints include complete pathological response, disease-free survival, and safety/tolerability.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene downgraded to Equal Weight from Overweight at Morgan Stanley
- Adagene Reports Promising Results in Colorectal Cancer Study
- Adagene announces updated data from Phase 1b/2 study of muzastotug, keytruda
- Adagene price target raised to $8 from $5 at H.C. Wainwright
- Adagene to host virtual KOL event to discuss SAFEbodyADG126
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue